{"entity":{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","aka":[],"tldr":"Protara Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials of TARA-002 in bladder & urothelial cancer.","summary":"Protara Therapeutics, based in New York, the United States, is a biotechnology company. Protara is a biopharmaceutical company developing investigational therapies for oncology and rare diseases. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TARA-002 in bladder & urothelial cancer. The largest, NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), plans to enrol 284 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.protaratx.com/"},{"label":"ClinicalTrials.gov: trials led by Protara Therapeutics","url":"https://clinicaltrials.gov/search?lead=Protara%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["tara-002"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05951179"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"New York","country":"US","companyType":"biotech","website":"https://www.protaratx.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/protara-therapeutics/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/"}],"trial":[{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/"},{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/"}]}}